Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Allogene Therapeutics (ALLO), a clinical-stage biotechnology company focused on developing allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease treatment, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. David Chang, M.D., Ph.D., the company's President, CEO, and Co-Founder, will deliver a presentation at the Westin St. Francis in San Francisco on Wednesday, January 15, 2025, at 3:00 PM PT/ 6:00 PM ET.

A live audio webcast will be available on Allogene's website under the Investors tab, with a replay accessible for approximately 30 days following the presentation.

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene, will present at the 43rd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco.

43^rd Annual J.P. Morgan Healthcare Conference
Wednesday, January 15, 2025
3:00PM PT/ 6:00PM ET

A live audio webcast of the presentation will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section.

Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T^™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factor” heading in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com

FAQ

When is Allogene Therapeutics (ALLO) presenting at the 2025 J.P. Morgan Healthcare Conference?

Allogene Therapeutics will present on Wednesday, January 15, 2025, at 3:00 PM PT/ 6:00 PM ET at the Westin St. Francis in San Francisco.

How can investors access Allogene's (ALLO) J.P. Morgan Healthcare Conference presentation?

Investors can access the live audio webcast on Allogene's website (www.allogene.com) under the Investors tab in the News and Events section. A replay will be available for approximately 30 days after the presentation.

What is Allogene Therapeutics (ALLO) currently developing?

Allogene Therapeutics is developing allogeneic CAR T (AlloCAR T™) products for the treatment of cancer and autoimmune disease.

Who will represent Allogene Therapeutics (ALLO) at the 2025 J.P. Morgan Healthcare Conference?

David Chang, M.D., Ph.D., who serves as President, Chief Executive Officer and Co-Founder of Allogene, will represent the company at the conference.